Dr. Pam Says This Pending Drug Approval is Not Viagra For Women

Dr. Pam (Dr. Pamela Gaudry)- The leading authority on Menopause says this is not Viagra for women and has also given important information about the pending drug approval for women experiencing low sexual drive and who are seeking help for change. Dr. Pam helps women who suffer with consequences of menopause and need help to nurture relationships and build back self-esteem.

In 1998, the FDA approved Viagra® for men to help them achieve and maintain an erection during a sexual encounter. It works by increasing and maintaining the blood flow to the penis. Although pharmaceutical companies and physicians knew that a drug which would help low-libido in women would be very beneficial to some women, it was known that women’s bodies do not work the same way. Many women have tried Viagra®, but, with no surprise to the medical profession, it really hasn’t helped increase their libido.

Fast forward to around 2010. A German pharmaceutical company was testing a drug as a new anti-depressant. It did not work that well for depression, but many of the women who were taking part in the clinical trials reported that they had more sexual interest than before they started the trials.


Flibanserin®: Referred To As The Viagra For Women is Pending FDA Approval

Now 17 years after the approval of Viagra® for men, the FDA may approve a drug to help women who are upset by the fact that they do not desire intercourse very often. Flibanserin®, sometimes referred to as the “female Viagra®,” is pending FDA approval for pre-menopausal women with hypoactive sexual desire disorder. But, it is not Viagra®, and it doesn’t work like Viagra®. Flibanserin® works by briefly stimulating some specific receptors in the brain (dopamine and norepinephrine) and by briefly blocking others (serotonin) which seems to control the brain’s motivation and reward center; this has a positive effect on some women’s sexual craving.


Some Women Have Doubled Their Satisfying Sexual Experiences

Unfortunately, not all women are going to respond to this drug, but the women who do, may see up to a doubling of their satisfying sexual encounters. Remember, this drug is for women who have a low desire for sex. So…if a woman is only having intercourse twice a month starts having intercourse 4x a month, it may decrease her distress about her lack of desire. About 20% of women suffer from hypoactive sexual desire disorder, and this drug may help so many of them feel better about themselves and their relationships. There are many women out there that are not interested in sex or having sexual intercourse, and they are not bothered in the least by this fact; this drug is not for them. This drug is not intended to make hypersexual women out of women who have little or no desire. It is meant to help women who have little or no sexual desire and are distressed by this, to increase their desire to what they perceive is a more normal level. Like all pharmaceuticals, there are some risks to taking Flibanserin®, but the patient and her physician must sit down, discuss, and evaluate the risks verses the potential benefits. If the FDA approves the drug in August, 2015, some women may finally have some help to this distressing problem.

You Might Also Enjoy...

Mammogram Mayhem

I have spent a lot of time on the phone recently with several patients trying to explain a new law that went into effect in Georgia on July 1, 2019 that requires mammography providers to tell their patients about their breast density.